Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
暂无分享,去创建一个
[1] M. Fukuoka,et al. A phase I study of GW572016 in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Birnbaum,et al. Akt/Protein Kinase B Isoforms Are Differentially Regulated by Epidermal Growth Factor Stimulation* , 2000, The Journal of Biological Chemistry.
[3] Hong Ma,et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.
[4] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[5] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[6] K. Lackey,et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.
[7] P. Leder,et al. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes , 1998, Oncogene.
[8] R. Bianco,et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.
[9] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.